PTEN and ovarian endometrioid adenocarcinoma: The aberrancy rate for PTEN was lower across the spectrum in ovarian versus endometrial lesions (e.g., 27.6% in ovarian endometrioid adenocarcinomas [this study] relative to 59.5% in endometrioid adenocarcinomas28).